Gain Therapeutics prices $7M public offering of common stock and warrants

Gain Therapeutics, Inc.

Offering of 4,501,640 common shares and warrants to purchase 2,250,820 shares at $3.11 per set.
Gross proceeds of $7.0M; net proceeds expected ~$6.3M after underwriting fees and expenses.
Proceeds to fund clinical development of lead candidate GT-02287 for GBA1 Parkinson's disease.
Warrants exercisable at $1.65 per share, immediately exercisable, expire in 5 years.
Newbridge Securities sole book-runner; closing expected July 17, 2025.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.